title: Management options in triple-negative breast cancer.
abstract: Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers, and claudin-low cancers, is currently being explored in hopes of finding the targets for novel biologics and chemotherapeutic agents. In this review, we aim to give a broad overview of the disease's nomenclature and epidemiology, as well as the basic mechanisms of emerging targeted therapies and their performance in clinical trials to date.
authors.affiliation: David Geffen School of Medicine, The University of California at Los Angeles, Los Angeles, California, USA.
authors.forename: Christina A
authors.initials: CA
authors.lastname: Minami
authors.forename: Debra U
authors.initials: DU
authors.lastname: Chung
authors.forename: Helena R
authors.initials: HR
authors.lastname: Chang